Fig. 6.

Aerobic metabolism is decreased in Ptpmt1-ablated cells. (A) 4-OHT- or DMSO-treated Ptpmt1^+/+/ER-Cre⁺ and Ptpmt1^flox/flox/ER-Cre⁺ ES cells were assayed for total cellular ATP levels as described in Materials and Methods. Experiments were performed with three independent cell pools for each group. Results shown are means ± standard deviations of three independent experiments. (B) ROS levels in 4-OHT or DMSO-treated Ptpmt1^+/+/ER-Cre⁺ and Ptpmt1^flox/flox/ER-Cre⁺ ES cells were determined as described in Materials and Methods. Experiments were performed with 3 cell pools for each group. Results shown are means ± standard deviations. (C) Oxygen consumption rates of intact 4-OHT-treated Ptpmt1^+/+/ER-Cre⁺ and Ptpmt1^flox/flox/ER-Cre⁺ ES cells were measured following the addition of mitochondrial inhibitor (oligomycin, 5 μM), uncoupling agent (FCCP, 1 μM), and respiratory chain inhibitor (rotenone, 5 μM) as described in Materials and Methods. Experiments were performed with 3 cell pools for each group. Results shown are means ± standard deviations. (D, E) Oxygen consumption (D) and glycolytic activities (E) of intact 4-OHT-treated Ptpmt1^+/+/ER-Cre⁺ and Ptpmt1^flox/flox/ER-Cre⁺ MEFs were measured following the addition of mitochondrial inhibitor (oligomycin, 1 μM), uncoupling agent (FCCP, 300 nM), and respiratory chain inhibitor (rotenone, 600 nM). (E) Baseline extracellular acidification rates are shown. Experiments were performed with three independent cell pools for each group. Representative results from one pair of cell pools are shown.